Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
Status:
Not yet recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see if loncastuximab tesirine has any benefits at
dose levels researchers found acceptable in earlier studies in patients with related forms of
immune cell cancers. The researchers want to find out the effects (good and bad) that
loncastuximab tesirine has on the participant and the participant's condition.